WEST PHARMACEUTICAL SERVICES, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
WEST PHARMACEUTICAL SERVICES, INC. (WST) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $800.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-07-23
- WEST PHARMACEUTICAL SERVICES, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was $800.00K, a 83.67% decline year-over-year.
- WEST PHARMACEUTICAL SERVICES, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- WEST PHARMACEUTICAL SERVICES, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $29.90M, a 579.55% increase year-over-year.
- WEST PHARMACEUTICAL SERVICES, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $800.00K, a 70.37% decline year-over-year.
- WEST PHARMACEUTICAL SERVICES, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $39.80M, a 3.40% decline from fiscal 2024.
- WEST PHARMACEUTICAL SERVICES, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $41.20M, a 285.05% increase from fiscal 2023.
- WEST PHARMACEUTICAL SERVICES, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $10.70M, a 77.52% decline from fiscal 2022.
- WEST PHARMACEUTICAL SERVICES, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $47.60M, a 257.89% increase from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $800.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | $800.00K 10-Q · filed 2026-07-23 | $30.70M derived: sum of 3 quarters · filed 2026-07-23 | $31.50M derived: sum of 4 quarters · filed 2026-07-23 |
| 2026-03-31 | $0.00 10-Q · filed 2026-04-23 | $29.90M derived: sum of 2 quarters · filed 2026-04-23 | $30.70M derived: sum of 3 quarters · filed 2026-04-23 | $35.60M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-12-31 | $29.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $30.70M derived: sum of 2 quarters · filed 2026-02-17 | $35.60M derived: sum of 3 quarters · filed 2026-07-23 | $39.80M 10-K · filed 2026-02-17 |
| 2025-09-30 | $800.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-23 | $5.70M derived: sum of 2 quarters · filed 2026-07-23 | $9.90M 10-Q · filed 2025-10-23 | $14.30M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-06-30 | $4.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | $9.10M 10-Q · filed 2026-07-23 | $13.50M derived: sum of 3 quarters · filed 2026-07-23 | $16.20M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-03-31 | $4.20M 10-Q · filed 2026-04-23 | $8.60M derived: sum of 2 quarters · filed 2026-04-23 | $11.30M derived: sum of 3 quarters · filed 2026-04-23 | $41.20M derived: sum of 4 quarters · filed 2026-04-23 |
| 2024-12-31 | $4.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $7.10M derived: sum of 2 quarters · filed 2026-02-17 | $37.00M derived: sum of 3 quarters · filed 2026-02-17 | $41.20M 10-K · filed 2026-02-17 |
| 2024-09-30 | $2.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-23 | $32.60M derived: sum of 2 quarters · filed 2025-10-23 | $36.80M 10-Q · filed 2025-10-23 | $40.90M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $29.90M 10-Q · filed 2024-07-25 | $34.10M 10-Q · filed 2025-07-24 | $38.20M derived: sum of 3 quarters · filed 2026-02-17 | $41.30M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $4.20M 10-Q · filed 2025-04-24 | $8.30M derived: sum of 2 quarters · filed 2026-02-17 | $11.40M derived: sum of 3 quarters · filed 2026-02-17 | $14.30M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $4.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $7.20M derived: sum of 2 quarters · filed 2026-02-17 | $10.10M derived: sum of 3 quarters · filed 2026-02-17 | $10.70M 10-K · filed 2026-02-17 |
| 2023-09-30 | $3.10M 10-Q · filed 2023-10-26 | $6.00M derived: sum of 2 quarters · filed 2024-07-25 | $6.60M 10-Q · filed 2024-10-24 | $24.70M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | $2.90M 10-Q · filed 2024-07-25 | $3.50M 10-Q · filed 2024-07-25 | $21.60M derived: sum of 3 quarters · filed 2025-02-18 | $35.60M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | $600.00K 10-Q · filed 2024-04-25 | $18.70M derived: sum of 2 quarters · filed 2025-02-18 | $32.70M derived: sum of 3 quarters · filed 2025-02-18 | $38.50M derived: sum of 4 quarters · filed 2025-02-18 |
| 2022-12-31 | $18.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $32.10M derived: sum of 2 quarters · filed 2025-02-18 | $37.90M derived: sum of 3 quarters · filed 2025-02-18 | $47.60M 10-K · filed 2025-02-18 |
| 2022-09-30 | $14.00M 10-Q · filed 2023-10-26 | $19.80M derived: sum of 2 quarters · filed 2023-10-26 | $29.50M 10-Q · filed 2023-10-26 | $42.00M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $5.80M 10-Q · filed 2023-07-27 | $15.50M 10-Q · filed 2023-07-27 | $28.00M derived: sum of 3 quarters · filed 2024-02-20 | $28.00M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $9.70M 10-Q · filed 2023-04-27 | $22.20M derived: sum of 2 quarters · filed 2024-02-20 | $22.20M derived: sum of 3 quarters · filed 2024-02-20 | $22.50M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $12.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $12.50M derived: sum of 2 quarters · filed 2024-02-20 | $12.80M derived: sum of 3 quarters · filed 2024-02-20 | $13.30M 10-K · filed 2024-02-20 |
| 2021-09-30 | $0.00 10-Q · filed 2022-10-27 | $300.00K derived: sum of 2 quarters · filed 2022-10-27 | $800.00K 10-Q · filed 2022-10-27 | $2.30M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $300.00K 10-Q · filed 2022-07-28 | $800.00K 10-Q · filed 2022-07-28 | $2.30M derived: sum of 3 quarters · filed 2023-02-21 | $2.60M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $500.00K 10-Q · filed 2022-04-28 | $2.00M derived: sum of 2 quarters · filed 2023-02-21 | $2.30M derived: sum of 3 quarters · filed 2023-02-21 | $4.10M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $1.80M derived: sum of 2 quarters · filed 2023-02-21 | $3.60M derived: sum of 3 quarters · filed 2023-02-21 | $6.10M 10-K · filed 2023-02-21 |
| 2020-09-30 | $300.00K 10-Q · filed 2021-10-28 | $2.10M derived: sum of 2 quarters · filed 2021-10-28 | $4.60M 10-Q · filed 2021-10-28 | $5.30M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | $1.80M 10-Q · filed 2021-07-30 | $4.30M 10-Q · filed 2021-07-30 | $5.00M derived: sum of 3 quarters · filed 2022-02-22 | $5.30M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | $2.50M 10-Q · filed 2021-04-30 | $3.20M derived: sum of 2 quarters · filed 2022-02-22 | $3.50M derived: sum of 3 quarters · filed 2022-02-22 | $4.80M derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $1.00M derived: sum of 2 quarters · filed 2022-02-22 | $2.30M derived: sum of 3 quarters · filed 2022-02-22 | $9.10M 10-K · filed 2022-02-22 |
| 2019-09-30 | $300.00K 10-Q · filed 2020-10-23 | $1.60M derived: sum of 2 quarters · filed 2020-10-23 | $8.40M 10-Q · filed 2020-10-23 | |
| 2019-06-30 | $1.30M 10-Q · filed 2020-07-24 | $8.10M 10-Q · filed 2020-07-24 | ||
| 2019-03-31 | $6.80M 10-Q · filed 2020-04-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |